Emerging therapeutic targets in systemic sclerosis.

O'Reilly, Steven

Abstract

Systemic sclerosis is an autoimmune connective tissue disease which is characterised by vascular perturbations, inflammation, and fibrosis. Although huge progress recently into the underlying molecular pathways that are perturbed in the disease, currently no therapy exists that targets the fibrosis element of the disease and consequently there is a huge unmet medical need. Emerging studies reveal new dimensions of complexity, and multiple aberrant pathways have been uncovered that have shed light on disturbed signalling in the disease, primarily in inflammatory pathways that can be targeted with repurposed drugs. Pre-clinical animal models using these inhibitors have yielded proof of concept for targeting these signalling systems and progressing to clinical trials. This review will examine the recent evidence of new perturbed pathways in SSc and how these can be targeted with new or repurposed drugs to target a currently intractable disease. [Abstract copyright: © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.]

Citation

O'Reilly, S. (2024). Emerging therapeutic targets in systemic sclerosis. Journal of Molecular Medicine, 102(4), 465-478. https://doi.org/10.1007/s00109-024-02424-w

• Journal Article Type: Article
• Acceptance Date: Jan 25, 2024
• Online Publication Date: Feb 22, 2024
• Publication Date: 2024-04
• Deposit Date: May 21, 2024
• Journal: Journal of molecular medicine (Berlin, Germany)
• Print ISSN: 0946-2716
• Electronic ISSN: 1432-1440
• Publisher: Springer
• Peer Reviewed: Peer Reviewed
• Volume: 102
• Issue: 4
• Pages: 465-478
• DOI: https://doi.org/10.1007/s00109-024-02424-w
• Keywords: Anifrolumab, Systemic sclerosis, Riociguat
• Public URL: https://durham-repository.worktribe.com/output/2313718